Ultragenyx Pharmaceutical Stock (NASDAQ:RARE)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$27.30

52W Range

$25.81 - $60.37

50D Avg

$34.70

200D Avg

$41.28

Market Cap

$2.58B

Avg Vol (3M)

$1.70M

Beta

0.26

Div Yield

-

RARE Company Profile


Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

1,294

IPO Date

Jan 31, 2014

Website

RARE Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 24Dec 23Dec 22
Royalty$274.81M$182.65M-
Product$285.42M$180.41M-
Collaboration And License-$71.18M$7.69M

Fiscal year ends in Dec 24 | Currency in USD

RARE Financial Summary


Dec 24Dec 23Dec 22
Revenue$560.23M$434.25M$363.33M
Operating Income$-535.97M$-569.21M$-648.92M
Net Income$-569.18M$-606.64M$-707.42M
EBITDA$-535.97M$-516.45M$-640.51M
Basic EPS$-6.29$-8.25$-10.12
Diluted EPS$-6.29$-8.25$-10.12

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts


Q1 25May 06, 25 | 5:00 PM
Q4 24Feb 13, 25 | 5:00 PM
Q3 24Nov 05, 24 | 5:00 PM

Peer Comparison


TickerCompany
QUREuniQure N.V.
MREOMereo BioPharma Group plc
PTCTPTC Therapeutics, Inc.
DAWNDay One Biopharmaceuticals, Inc.
AGIOAgios Pharmaceuticals, Inc.
BPMCBlueprint Medicines Corporation
BMRNBioMarin Pharmaceutical Inc.